Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer

Shinichi Fujiwara, Hisashi Wada, Hiroshi Miyata, Junji Kawada, Ryohei Kawabata, Hiroyoshi Nishikawa, Sacha Gnjatic, Christine Sedrak, Eiichi Sato, Yurika Nakamura, Mitsuru Sakakibara, Tatsuya Kanto, Eku Shimosegawa, Jun Hatazawa, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Eiichi NakayamaMasaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed. We performed chemoimmunotherapy involving the intratumoral administration of In-labeled dendritic cells (DC) in combination with preoperative chemotherapy in 5 esophageal cancer patients. Mature DC were generated and traced by scintigraphy after their administration. No adverse events that were directly related to the intratumoral DC administration were observed. Delayed-type hypersensitivity skin tests against keyhole limpet hemocyanin, which was added to the culture medium, detected a positive response in 3 patients, and keyhole limpet hemocyanin antibody production was observed in 4 patients, suggesting that intratumorally administered DC migrate to the lymph nodes, where they function as antigen-presenting cells. However, scintigraphic images obtained after the DC administration demonstrated that the DC remained at the esophageal tumor injection sites in all cases, and no DC accumulation was observed elsewhere. The accumulation of CD83 cells in the primary tumor was also observed in 2 out of 4 patients in an immunohistochemical analysis using surgically resected specimens. Although the induction of tumor-specific immune responses during chemoimmunotherapy was also analyzed in enzyme-linked immunosorbent assay against 28 tumor antigens, none of the antibodies against the antigens displayed enhanced titers. No changes of NY-ESO-1-specific cellular immune response was observed in a patient who displayed NY-ESO-1 antibody production before the DC administration. These results suggest that the intratumoral administration of In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalJournal of Immunotherapy
Volume35
Issue number6
DOIs
Publication statusPublished - Jul 1 2012
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Dendritic Cells
Clinical Trials
Drug Therapy
Antibody Formation
Neoplasms
Lymph Nodes
Delayed Hypersensitivity
Neoplasm Antigens
Antigen-Presenting Cells
Skin Tests
Cellular Immunity
Radionuclide Imaging
Cell Movement
Culture Media
Enzyme-Linked Immunosorbent Assay
Antigens
Injections
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. / Fujiwara, Shinichi; Wada, Hisashi; Miyata, Hiroshi; Kawada, Junji; Kawabata, Ryohei; Nishikawa, Hiroyoshi; Gnjatic, Sacha; Sedrak, Christine; Sato, Eiichi; Nakamura, Yurika; Sakakibara, Mitsuru; Kanto, Tatsuya; Shimosegawa, Eku; Hatazawa, Jun; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Nakajima, Kiyokazu; Takiguchi, Shuji; Nakayama, Eiichi; Mori, Masaki; Doki, Yuichiro.

In: Journal of Immunotherapy, Vol. 35, No. 6, 01.07.2012, p. 513-521.

Research output: Contribution to journalArticle

Fujiwara, S, Wada, H, Miyata, H, Kawada, J, Kawabata, R, Nishikawa, H, Gnjatic, S, Sedrak, C, Sato, E, Nakamura, Y, Sakakibara, M, Kanto, T, Shimosegawa, E, Hatazawa, J, Takahashi, T, Kurokawa, Y, Yamasaki, M, Nakajima, K, Takiguchi, S, Nakayama, E, Mori, M & Doki, Y 2012, 'Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer', Journal of Immunotherapy, vol. 35, no. 6, pp. 513-521. https://doi.org/10.1097/CJI.0b013e3182619cb4
Fujiwara, Shinichi ; Wada, Hisashi ; Miyata, Hiroshi ; Kawada, Junji ; Kawabata, Ryohei ; Nishikawa, Hiroyoshi ; Gnjatic, Sacha ; Sedrak, Christine ; Sato, Eiichi ; Nakamura, Yurika ; Sakakibara, Mitsuru ; Kanto, Tatsuya ; Shimosegawa, Eku ; Hatazawa, Jun ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Nakayama, Eiichi ; Mori, Masaki ; Doki, Yuichiro. / Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. In: Journal of Immunotherapy. 2012 ; Vol. 35, No. 6. pp. 513-521.
@article{dab1dae7ca1a490b9ccfe27d22ec97ca,
title = "Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer",
abstract = "Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed. We performed chemoimmunotherapy involving the intratumoral administration of In-labeled dendritic cells (DC) in combination with preoperative chemotherapy in 5 esophageal cancer patients. Mature DC were generated and traced by scintigraphy after their administration. No adverse events that were directly related to the intratumoral DC administration were observed. Delayed-type hypersensitivity skin tests against keyhole limpet hemocyanin, which was added to the culture medium, detected a positive response in 3 patients, and keyhole limpet hemocyanin antibody production was observed in 4 patients, suggesting that intratumorally administered DC migrate to the lymph nodes, where they function as antigen-presenting cells. However, scintigraphic images obtained after the DC administration demonstrated that the DC remained at the esophageal tumor injection sites in all cases, and no DC accumulation was observed elsewhere. The accumulation of CD83 cells in the primary tumor was also observed in 2 out of 4 patients in an immunohistochemical analysis using surgically resected specimens. Although the induction of tumor-specific immune responses during chemoimmunotherapy was also analyzed in enzyme-linked immunosorbent assay against 28 tumor antigens, none of the antibodies against the antigens displayed enhanced titers. No changes of NY-ESO-1-specific cellular immune response was observed in a patient who displayed NY-ESO-1 antibody production before the DC administration. These results suggest that the intratumoral administration of In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.",
author = "Shinichi Fujiwara and Hisashi Wada and Hiroshi Miyata and Junji Kawada and Ryohei Kawabata and Hiroyoshi Nishikawa and Sacha Gnjatic and Christine Sedrak and Eiichi Sato and Yurika Nakamura and Mitsuru Sakakibara and Tatsuya Kanto and Eku Shimosegawa and Jun Hatazawa and Tsuyoshi Takahashi and Yukinori Kurokawa and Makoto Yamasaki and Kiyokazu Nakajima and Shuji Takiguchi and Eiichi Nakayama and Masaki Mori and Yuichiro Doki",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/CJI.0b013e3182619cb4",
language = "English",
volume = "35",
pages = "513--521",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer

AU - Fujiwara, Shinichi

AU - Wada, Hisashi

AU - Miyata, Hiroshi

AU - Kawada, Junji

AU - Kawabata, Ryohei

AU - Nishikawa, Hiroyoshi

AU - Gnjatic, Sacha

AU - Sedrak, Christine

AU - Sato, Eiichi

AU - Nakamura, Yurika

AU - Sakakibara, Mitsuru

AU - Kanto, Tatsuya

AU - Shimosegawa, Eku

AU - Hatazawa, Jun

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Nakayama, Eiichi

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed. We performed chemoimmunotherapy involving the intratumoral administration of In-labeled dendritic cells (DC) in combination with preoperative chemotherapy in 5 esophageal cancer patients. Mature DC were generated and traced by scintigraphy after their administration. No adverse events that were directly related to the intratumoral DC administration were observed. Delayed-type hypersensitivity skin tests against keyhole limpet hemocyanin, which was added to the culture medium, detected a positive response in 3 patients, and keyhole limpet hemocyanin antibody production was observed in 4 patients, suggesting that intratumorally administered DC migrate to the lymph nodes, where they function as antigen-presenting cells. However, scintigraphic images obtained after the DC administration demonstrated that the DC remained at the esophageal tumor injection sites in all cases, and no DC accumulation was observed elsewhere. The accumulation of CD83 cells in the primary tumor was also observed in 2 out of 4 patients in an immunohistochemical analysis using surgically resected specimens. Although the induction of tumor-specific immune responses during chemoimmunotherapy was also analyzed in enzyme-linked immunosorbent assay against 28 tumor antigens, none of the antibodies against the antigens displayed enhanced titers. No changes of NY-ESO-1-specific cellular immune response was observed in a patient who displayed NY-ESO-1 antibody production before the DC administration. These results suggest that the intratumoral administration of In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.

AB - Esophageal cancer is a highly aggressive disease, and improved modalities for its treatment are needed. We performed chemoimmunotherapy involving the intratumoral administration of In-labeled dendritic cells (DC) in combination with preoperative chemotherapy in 5 esophageal cancer patients. Mature DC were generated and traced by scintigraphy after their administration. No adverse events that were directly related to the intratumoral DC administration were observed. Delayed-type hypersensitivity skin tests against keyhole limpet hemocyanin, which was added to the culture medium, detected a positive response in 3 patients, and keyhole limpet hemocyanin antibody production was observed in 4 patients, suggesting that intratumorally administered DC migrate to the lymph nodes, where they function as antigen-presenting cells. However, scintigraphic images obtained after the DC administration demonstrated that the DC remained at the esophageal tumor injection sites in all cases, and no DC accumulation was observed elsewhere. The accumulation of CD83 cells in the primary tumor was also observed in 2 out of 4 patients in an immunohistochemical analysis using surgically resected specimens. Although the induction of tumor-specific immune responses during chemoimmunotherapy was also analyzed in enzyme-linked immunosorbent assay against 28 tumor antigens, none of the antibodies against the antigens displayed enhanced titers. No changes of NY-ESO-1-specific cellular immune response was observed in a patient who displayed NY-ESO-1 antibody production before the DC administration. These results suggest that the intratumoral administration of In-labeled mature DC during chemotherapy does not lead to detectable DC migration from the primary tumor to the draining lymph nodes, and therefore, might not achieve an optimal clinical response.

UR - http://www.scopus.com/inward/record.url?scp=84864196063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864196063&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3182619cb4

DO - 10.1097/CJI.0b013e3182619cb4

M3 - Article

C2 - 22735809

AN - SCOPUS:84864196063

VL - 35

SP - 513

EP - 521

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -